Kevin Kunzmann on Muck Rack

Kevin Kunzmann

Glassboro
As seen in: MJH Life Sciences, TIME, PLOS, The Morning Call, Lehigh Valley Live, The Express-Times, NewsBreak, Bryan-College Station Eagle, Roanoke Times, HCP Live, Laredo Morning Times and
Covering medicine, tweeting about it too. Got my degree from @RowanUniversity, and my anxiety from the @Mets.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Kevin

Contact Kevin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

FDA Approves Awiqli (Insulin Icodec) as First Once-Weekly Basal Insulin for Type 2 Diabetes

|
By Kevin Kunzmann
| consultantlive.com
The US Food and Drug Administration (FDA) has approved Awiqli (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly basal insulin available in the US, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D). The decision makes insulin icodec the first new class of basal insulin to reach US patients in more than 2 decades.
Open in Who Shared View Duplicates (2) Issue with article?

Ophthalmic drug shortages more frequent, longer lasting than average

|
By Martin Harp , Kevin Kunzmann, Lynda Charters 
| Modern Retina
Ophthalmic drug shortages comprise approximately 15% of all active drug shortages in the US, according to a retrospective analysis of nationally representative data from the University of Utah.1 Investigators led by Ian F. Pitha, MD, PhD, an ophthalmologist at the John A. Moran Eye Center, found that not only do ophthalmic drugs constitute a significant rate of the drug shortages reported in the US since 2001 — but their shortages generally last nearly a month longer than average.
Open in Who Shared Issue with article?

FDA approves mirdametinib for adult and pediatric patients with neurofibromatosis type 1

|
By Kevin Kunzmann
| The Educated Patient
The US Food and Drug Administration (FDA) has approved mirdametinib (Gomekli) for adults and children aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) that cannot be completely removed with surgery. This approval offers a new treatment option for families facing one of the more challenging complications of NF1.
Open in Who Shared Issue with article?
See all 984 licensed articles (4,051 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Kevin

Contact Kevin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified